TherapeuticsMD, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marlan D. Walker
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 951 Yamato Road Boca Raton FL United States of America 33431
- IPO Date
- May 9, 2007
- CIK
- 0000025743
- Website
- therapeuticsmd.com
- Similar Companies
- Business
- TherapeuticsMD, Inc. operates as a pharmaceutical royalty company focused on women's healthcare in the United States and select international markets. The company licenses its portfolio of prescription products—including IMVEXXY (estradiol vaginal inserts) for moderate-to-severe dyspareunia due to vulvovaginal atrophy in menopause; BIJUVA (estradiol and progesterone softgel capsules) for moderate-to-severe vasomotor symptoms due to menopause; and ANNOVERA (segesterone and ethinyl estradiol vaginal ring), a ring-shaped contraceptive system providing 13 cycles of protection—to exclusive partners such as Mayne Pharma for commercialization; it also receives royalties on branded and generic prenatal vitamins marketed under the BocaGreenMD and vitaMedMD names, distributed through wholesale and retail pharmacy channels. Founded in 2008 and headquartered in Boca Raton, Florida, TherapeuticsMD generates revenue primarily from royalty streams under long-term agreements, including a 20-year deal with Mayne Pharma established in December 2022 that provided an upfront payment of approximately $153 million and ongoing royalties tied to net sales. In recent developments, the company reported third quarter 2025 financial results on November 12, 2025, with licensing revenue of $784,000 largely from the Mayne agreement, cash and equivalents of $7.1 million as of September 30, 2025, and a net loss reduction; it continues to evaluate strategic alternatives, including potential mergers, acquisitions, business combinations, or asset sales, amid a pivot to a pure royalty model following the cessation of internal R&D and direct sales in late 2022.
TherapeuticsMD Announces First Quarter 2026 Financial Results
TherapeuticsMD Announces Full Year 2025 Financial Results
TherapeuticsMD Announces Third Quarter 2025 Financial Results
TherapeuticsMD Announces Second Quarter 2025 Financial Results
TherapeuticsMD Announces First Quarter 2025 Financial Results
TherapeuticsMD Announces Full Year 2024 Financial Results
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD Announces Third Quarter 2023 Financial Results
TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD Announces First Quarter 2023 Financial Results
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma